FDA Retracts Approval of Eli Lilly’s COVID Drug

A recent Reuters article noted that the FDA has taken away the emergency use authorization of bebtelovimab,  Eli Lilly’s COVID-19 monoclonal antibody treatment. The agency said the drug is not expected to neutralize the dominant subvariants of Omicron. The decision narrows the treatment options to four: Pfizer’s Paxlovid and Merck’s Lagevrio, Gilead’s Veklury, and AstraZeneca’s Evusheld. Commercial distribution of bebteloviman bas been halted until further notice from the agency.